Premium
Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer
Author(s) -
Economides Minas P.,
Amit Moran,
Mahale Parag S.,
Hosry Jeff J.,
Jiang Ying,
Bharadwaj Uddalak,
Sturgis Erich M.,
Torres Harrys A.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31146
Subject(s) - medicine , hazard ratio , cancer , hepatitis c virus , gastroenterology , confidence interval , hepatitis c , retrospective cohort study , cirrhosis , cohort , epidemiology , stage (stratigraphy) , surgery , immunology , virus , paleontology , biology
BACKGROUND Although an association between hepatitis C virus (HCV) infection and oropharyngeal cancers (OPCs) has been reported, to the authors' knowledge the clinical significance of this epidemiological finding remains unknown. Therefore, the authors analyzed the oncologic outcomes of HCV‐infected patients with OPCs. METHODS In this retrospective cohort study, all patients with OPCs who were seen at The University of Texas MD Anderson Cancer Center between January 2004 and December 2015 were reviewed. HCV infection was defined as detectable HCV RNA in the serum. Five‐year overall survival and progression‐free survival rates were compared between patients infected with HCV and those not infected. RESULTS A total of 161 patients were examined. The majority of the patients were white (141 patients; 88%) and male (132 patients; 82%) and had TNM stage III or IV disease (147 patients; 91%). The OPC involved the tonsils (83 patients; 52%), base of the tongue (67patients; 42%), or the soft palate (11 patients; 7%). The median follow‐up after an OPC diagnosis was 3 years (range, 1‐13 years). HCV‐infected patients (25 patients) and HCV‐uninfected patients (136 patients) were comparable with regard to smoking and alcohol status. In multivariate analysis, HCV was associated with increased cancer‐specific mortality (hazard ratio, 2.15; 95% confidence interval, 1.08‐6.85 [ P = .02]) and risk of OPC progression (hazard ratio, 5.42; 95% confidence interval, 2.64‐11.14 [ P = .0008]) independent of age and cirrhosis status. Antivirals were administered after the diagnosis of OPC in 8 of the 25 HCV‐infected patients (32%). HCV‐infected patients who received antivirals were found to have better 5‐year overall survival (70% vs 12%; P = .005) and progression‐free survival (72% vs 19%; P = .005) compared with patients who did not. CONCLUSIONS The early detection of HCV is important in patients with OPC because this infection may affect their oncologic outcomes. Cancer 2018;124:960‐5. © 2017 American Cancer Society .